The use of atmospheric pressure nonthermal plasma represents an interesting and novel approach for the decontamination of surfaces colonized with microbial biofilms that exhibit enhanced tolerance to antimicrobial challenge. In this study, the influence of an atmospheric pressure nonthermal plasma jet, operated in a helium and oxygen gas mixture under ambient pressure, was evaluated against biofilms of Bacillus cereus, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. Within < 4 min of plasma exposure, complete eradication of the two Gram-positive bacterial biofilms was achieved. Although Gram-negative biofilms required longer treatment time, their complete eradication was still possible with 10 min of exposure. Whilst this study provides useful proof of concept data on the use of atmospheric pressure plasmas for the eradication of bacterial biofilms in vitro, it also demonstrates the critical need for improved understanding of the mechanisms and kinetics related to such a potentially significant approach.
Atmospheric pressure nonthermal plasmas (also referred to as cold nonequilibrium plasmas) are emerging as a new development for biomedical technologies. They are very efficient sources of highly reactive neutral particles [e.g. reactive oxygen and nitrogen species (RONS)], charged particles (ions and electrons), radiation (from UV to IR) and electromagnetic fields (Moisan et al., 2002; O'Connell et al., 2011) . The relatively light electrons are not in thermodynamic equilibrium with the background gas owing to the largely different masses. The background gas, which is the dominating constituent, is close to ambient temperature, whilst the electrons are hotter and can thus drive a reactive environment through excitation, ionization and dissociation processes. Cold plasmas have been shown to trigger complex biochemical processes, resulting in physical and chemical modifications to biological matter. Potential applications include, for example, cancer therapeutics, development of new pharmaceuticals, and treatment of infectious and noninfectious diseases, such as nosocomial infections, cystic fibrosis and neurodegenerative diseases.
In the 1960s, the first successful use of nonthermal plasma for the decontamination of surfaces was reported using a low-pressure (below 1 Torr) plasma (Montie et al., 2000) . Some low-pressure plasmas operating with active vapours, such as hydrogen peroxide vapour, have already been approved by U.S. FDA for sterilization purposes (Rutala et al., 1998) but such approaches require the use of special vacuum chambers with the associated cost, limited reactor volume, limited to vacuum-compatible material and long cycle time (Montie et al., 2000) , factors that limit the utility of these systems for antimicrobial applications. During the past two decades, the development of stable nonthermal plasmas at ambient pressure and temperature, such as that described in Sousa et al., 2011 ; has led to an explosion of interest in a wide range of diverse applications as a result of their favourable characteristics including simple design, cost efficiency, low operation temperature and the absence of harmful residues (Yardimci & Setlow, 2010) and has given rise, in significant part, to the new emerging and exciting field of plasma medicine.
The use of atmospheric pressure nonthermal plasmas (APNTPs) have been evaluated for many potential biomedical applications (Fridman et al., 2008; Kong et al., 2009) , including eradication of bacteria. Amongst the reactive species produced by these devices are RONS such as ozone, atomic oxygen, superoxide, peroxide, hydroxyl radicals and nitric oxide (Gaunt et al., 2006) . The damaging effects of individual RONS on both prokaryotic and eukaryotic cells are well documented via their ability to react with various cellular biomacromolecules including DNA, lipids and proteins (Montie et al., 2000; Gaunt et al., 2006) . However, also important to consider within the plasma environment are the influences of synergistic mechanisms with multiple species. The significant problem of microbial resistance towards such a treatment is less likely to occur because of the range and diversity of the active agents generated by plasma.
Despite an increasing interest in microbial inactivation by APNTPs (as evidenced by a significant increase in the numbers of publications on the subject in the past 10 years), much less attention has been directed towards treatment of bacterial biofilms (Abramzon et al., 2006; Salamitou et al., 2009; Joshi et al., 2010) , which represent the predominant mode of microbial growth in both natural and clinical settings. Biofilms are known to constitute a protected mode of bacterial growth (Costerton et al., 1999) , and cells within biofilms exhibit significantly enhanced tolerance, compared to planktonic bacteria, to antimicrobial challenge (Costerton et al., 1999; HallStoodley et al., 2004) and host defence mechanisms (Adair et al., 1999; Costerton et al., 1999) . Therefore, any novel method of microbial decontamination, eradication or infection control, such as APNTPs, should be evaluated in the context of microbial biofilm eradication, as a more physiologically relevant assay. In this study, the activity of an in-house-designed APNTP jet will be investigated against biofilms of the clinically significant bacteria: Bacillus cereus, Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
The plasma jet used in this study (similar to that previously described by ) consists of a capillary dielectric quartz tube (inner diameter, 4 mm; outer diameter, 6 mm) surrounded by two tubular copper electrodes (2 mm wide) and separated by a distance of 25 mm. A high-voltage pulse source (Hai den, PHK-2k) with a repetition rate of 20 kHz and voltage amplitude of 6 kV was applied across the electrodes. The plasma jet was operated with a gas mixture containing 0.5% oxygen and 99.5% helium, with a total flow rate of 2 standard litre per minute (SLM). An intense plasma forms inside the glass tube between the two electrodes, and a relatively long, visible tapering plasma plume emerges from the end of the capillary tube, which can be then delivered to a target sample located within few centimetres from the main discharge zone.
The following microbial strains were used in this study: B. cereus NCTC 2599, S. aureus NCTC 10788, E. coli NCTC 10418 and P. aeruginosa PA01. All microbial strains used in this study were stored at À20°C in Microbank vials (Pro-Lab Diagnostics, Cheshire, UK) and were subcultured in Müller-Hinton broth (MHB) before testing. Müller-Hinton agar (MHA) was used as a solid growth media where appropriate including in inhibition zone experiment and standard plate count method.
For growth inhibition zone determination, an overnight culture of bacteria was diluted (9100) in sterile phosphate buffered saline (PBS), 100 lL of the diluted bacterial suspension was then spread evenly on the surface of MHA plate, and the plates were exposed (in duplicate) to the plasma plume for 0, 30, 120 or 240 s at a distance of 25 mm from the end of plasma jet tube. After exposure to the plasma, the plates were incubated at 37°C for 24 h in a static incubator, and bacterial growth on the agar surface was examined after incubation.
For construction of biofilm survival curves, bacterial biofilms were grown on the peg lid of Calgary Biofilm Device (commercially available as the MBEC Assay TM for Physiology and Genetics (P & G), Innovotech Inc., Edmonton, AB, Canada). An overnight culture of bacteria was adjusted to an optical density (OD 550 nm ) equivalent to 1 9 10 7 cfu mL
À1
. The standardized bacterial suspension was used to inoculate the Calgary Biofilm Device (with 150 lL in each well), which was then incubated at 37°C for 48 h in an orbital incubator. The bacterial inoculum was replaced by fresh growth medium (MHB) after the first 24 h of incubation. After 48 h of incubation, individual pegs were broken off the lid and rinsed with 200 lL of PBS for 1 min to remove any remaining planktonic or loosely adhered bacteria and inverted before being exposed to the plasma jet for up to 10 min with a distance of 15 mm between the plasma jet tube and top of the peg. After plasma exposure, the pegs were placed in the wells of a 96-well microtitre plate containing 200 lL PBS in each well and sonicated for 10 min. After sonication, the pegs were discarded and the resultant bacterial suspensions were used to determine the number of surviving bacterial cells by colony count method. All experiments were performed in triplicate.
Control plates (no plasma exposure) exhibited consistent bacterial lawns, whereas plasma-treated plates of all the tested bacterial strains were characterized by the presence of clear zones of growth inhibition. The diameter of each of these inhibition zones was measured and is reported in Table 1 . Although this experiment was not designed to provide quantitative measures of the antibacterial plasma activity per se, the measured inhibition zone diameters yield important information on the effective coverage area of the active species generated by the plasma, which in all cases extended significantly beyond the visible plasma plume that was < 5 mm in diameter at the point of contact with the sample. In addition, comparison of inhibition zone diameters between the different bacterial species may provide a useful indication of the relative activity of the plasma jet against each of the studied bacteria in its planktonic mode of growth. In this respect, P. aeruginosa proved least susceptible to inactivation by exposure to the plasma jet.
Biofilm survival curves (shown in Fig. 1 ) for the four species examined show that the atmospheric pressure plasma jet configuration used in this study exhibited excellent activity against biofilms of both Gram-positive and Gram-negative bacteria following relatively short exposure times. For instance, B. cereus and S. aureus biofilms were completely eradicated after 45 s and 2 min of plasma treatment, respectively. Biofilms of the Gramnegative bacteria proved more difficult to eradicate using this plasma jet; however, a complete eradication was still achieved with E. coli and P. aeruginosa after 8 and 10 min of plasma exposure, respectively.
Amongst the factors that may explain this variable response are the different structures and matrix compositions present in biofilms of each of these different bacterial strains. The decreased P. aeruginosa susceptibility might be explained by the presence of certain matrix constituents that may have an ability to neutralize the reactive species responsible for bacterial killing. In this regard, the exopolysaccharide alginate produced by P. aeruginosa was found to be able to scavenge the oxidant hypochlorite (Learn et al., 1987) and the types of free radicals known to be released by human leucocytes (Simpson et al., 1989) , which are basically similar to those produced by the plasma. Studying the interactions between the different matrix components with the plasma species will be helpful in understanding these effects.
However, even with the longer exposure times needed to inactivate Gram-negative biofilms, a complete eradication of biofilm cells was achieved for all the test organisms within a reasonable exposure time. These data demonstrate the utility of this approach for the elimination of bacterial biofilms in a rapid and noninvasive manner. Furthermore, the gas temperature of the current plasma plume, assumed to be the same as the measured rotational temperature of the nitrogen present, was found to be around 39°C (data not shown). The relatively low temperature is a critical feature of this system, which extends the potential use of this method to thermolabile agents and, importantly, in vivo applications involving viable tissues, for example, chronic biofilm-mediated wound infections. On the other hand, the plasma used in this study utilizes low-toxicity gases (He, O 2 ) and elaborates its activity by production of a mixture of charged particles, UV radiation and chemically reactive species that all decay within a few seconds after the treatment process. Therefore, this approach offers the additional benefit of being environmentally friendly with the absence of harmful residues. The efficacy of atmospheric pressure nonthermal plasma in the inactivation of a focussed panel of clinically significant microbial biofilms has been demonstrated in this study. Improved understanding of the exact mechanisms of bacterial destruction by the plasma, characterization of the activity-responsible plasma species, their interactions with the biological matter and its individual biomacromolecules, that is, DNA, proteins, lipids and polysaccharides, and the kinetics related to these processes are aspects requiring further study in the emerging field of plasma medicine. These, alongside biocompatibility and safety issues, will need to be addressed before the successful application of this approach for the eradication of microbial biofilms in in vivo scenarios.
